The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
iwNHL 2019 | Developing mantle cell lymphoma treatment for further success
John Kuruvilla, MD, FRCPC, Princess Margaret Cancer Centre, Toronto, ON, Canada, speaking at the 17th International Workshop on Non-Hodgkin Lymphoma, Boston, MA, reflects on the progression of mantle cell lymphoma treatment and the possibilities for further improvement, through building on the use of novel agents such as BTK inhibitors and BCL2 inhibitors combined with frontline chemotherapy earlier on in the treatment of patients.
